Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MDXG - MIMEDX GROUP, INC.

IEX Last Trade
9.39
0.010   0.106%

Share volume: 5,896
Last Updated: Fri 27 Dec 2024 02:30:05 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.33%

PREVIOUS CLOSE
CHG
CHG%
$9.38
0.01
0.11%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
54%
Profitability 66%
Dept financing 11%
Liquidity 50%
Performance 54%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.51%
1 Month
-1.08%
3 Months
61.59%
6 Months
36.88%
1 Year
1.67%
2 Year
235.66%
Key data
Stock price
$9.39
P/E Ratio 
10.90
DAY RANGE
$9.05 - $9.34
EPS 
$0.56
52 WEEK RANGE
$5.63 - $10.14
52 WEEK CHANGE
$2.58
MARKET CAP 
1.004 B
YIELD 
N/A
SHARES OUTSTANDING 
146.809 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/28/2024
BETA 
1.41
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$775,932
AVERAGE 30 VOLUME 
$760,456
Company detail
CEO: K. Todd Newton
Region: US
Website: mimedx.com
Employees: 870
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers and pressure ulcers. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors.

Recent news